Pharming Group (NASDAQ:PHAR - Get Free Report) fell 4.9% during mid-day trading on Tuesday . The stock traded as low as $8.83 and last traded at $8.70. 796 shares were traded during mid-day trading, a decline of 86% from the average session volume of 5,837 shares. The stock had previously closed at $9.15.
Analyst Ratings Changes
Several research firms have issued reports on PHAR. Jefferies Financial Group began coverage on shares of Pharming Group in a research note on Monday, December 9th. They issued a "buy" rating and a $14.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $37.00 price objective on shares of Pharming Group in a research note on Tuesday, December 17th.
View Our Latest Stock Analysis on PHAR
Pharming Group Stock Down 3.8 %
The firm has a market cap of $547.65 million, a price-to-earnings ratio of -30.96 and a beta of -0.10. The firm's 50 day moving average price is $9.21 and its two-hundred day moving average price is $8.56. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.
Institutional Investors Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its holdings in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 47,997 shares of the company's stock after buying an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Institutional investors own 0.03% of the company's stock.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Stories
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
